# Effect of Cannabinol, THCV, and CBD on Voluntary Alcohol Consumption > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-compounds-reduce-alcohol-consumption/ > **Published:** 2026-04-08T08:01:02-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:27:43-04:00 > **Clinical Summary:** Explore how cannabis compounds reduce alcohol consumption by targeting the endocannabinoid system, offering potential new approaches for alcohol use disorder. --- CED Clinical Relevance  #80High Clinical Relevance  Strong evidence or policy relevance with direct clinical implications. 🔬 Evidence Watch  |  CED Clinic Alcohol Use DisorderCbdCbnThcvAddiction Journal Alcohol and alcoholism (Oxford, Oxfordshire) Study Type Clinical Study Population Human participants Why This Matters This preclinical study addresses a critical clinical need, as current FDA-approved medications for alcohol use disorder have limited efficacy and adherence. [Cannabis compounds](https://cedclinic.com/cannabis-terpene-synergy-entourage-effect/) represent a novel therapeutic approach that may avoid the psychiatric side effects that derailed previous CB1 antagonist trials. Clinical Summary This animal study tested three non-psychoactive phytocannabinoids—cannabinol (CBN), tetrahydrocannabivarin (THCV), and cannabidiol (CBD)—in male rats with established voluntary [alcohol consumption patterns](https://cedclinic.com/cannabis-infused-drinks-may-help-people-cut-their-alcohol-intake-in-half/) over several months. The researchers administered each compound once daily for three days and monitored both alcohol consumption and potential side effects through water intake and body weight changes. The study represents early-stage research into whether these specific [cannabis compounds](https://cedclinic.com/cannabis-terpene-synergy-entourage-effect/) could reduce alcohol consumption without the severe psychiatric adverse effects that led to the failure of previous CB1 receptor antagonists in human trials. Dr. Caplan’s Take “While this is promising preclinical work, I remain cautious about extrapolating rat alcohol preference models to the complex neurobiological and psychosocial reality of human alcohol use disorder. The three-day dosing period is far too brief to assess meaningful clinical outcomes or safety profiles relevant to human treatment.” Clinical Perspective 🧠 Clinicians should view this as foundational research that may inform future human studies, but should not alter current evidence-based AUD treatment approaches. Patients asking about cannabis for alcohol reduction should be counseled that robust human [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) are needed before any therapeutic recommendations can be made. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Effect%20of%20cannabinol%2C%20tetrahydrocannabivarin%20and%20cannabidiol%20on%20voluntary%20alcoho...%20%40drcaplan&url=https%3A//pubmed.ncbi.nlm.nih.gov/41947574/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//pubmed.ncbi.nlm.nih.gov/41947574/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Effect%20of%20cannabinol%2C%20tetrahydrocannabivarin%20and%20cannabidiol%20on%20voluntary%20alcoho...%20--%20via%20%40drcaplan.bsky.social%20https%3A//pubmed.ncbi.nlm.nih.gov/41947574/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41947574/](https://pubmed.ncbi.nlm.nih.gov/41947574/) Table of Contents - [FAQ](#FAQ)[Could cannabis compounds be used to treat alcohol use disorder?](#Could_cannabis_compounds_be_used_to_treat_alcohol_use_disorder) - [Which cannabis compounds show the most promise for reducing alcohol consumption?](#Which_cannabis_compounds_show_the_most_promise_for_reducing_alcohol_consumption) - [Are there safety concerns with using cannabis compounds for alcohol use disorder treatment?](#Are_there_safety_concerns_with_using_cannabis_compounds_for_alcohol_use_disorder_treatment) - [How do these cannabis compounds work differently from previous alcohol addiction treatments?](#How_do_these_cannabis_compounds_work_differently_from_previous_alcohol_addiction_treatments) - [When might these cannabis-based treatments become available for patients with alcohol use disorder?](#When_might_these_cannabis-based_treatments_become_available_for_patients_with_alcohol_use_disorder) - [Related](#Related) ## FAQ #### Could cannabis compounds be used to treat alcohol use disorder? Research suggests certain non-psychoactive phytocannabinoids like CBD, CBN, and THCV may help reduce alcohol consumption by targeting the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/). This approach could offer a safer alternative to previously tested CB1 receptor antagonists, which failed in [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) due to severe psychiatric side effects. #### Which cannabis compounds show the most promise for reducing alcohol consumption? The study examined three compounds: cannabinol (CBN) as a CB1 receptor partial agonist, tetrahydrocannabivarin (THCV) as a neutral antagonist, and cannabidiol (CBD) as a negative allosteric modulator. All three demonstrated potential in reducing voluntary alcohol consumption in preclinical studies with different mechanisms of action on the CB1 receptor. #### Are there safety concerns with using cannabis compounds for alcohol use disorder treatment? The study monitored potential side effects by tracking changes in water consumption, body weight, and other physiological parameters. Non-psychoactive phytocannabinoids appear to have a better safety profile compared to synthetic CB1 antagonists, though more research is needed to establish their clinical safety in humans. #### How do these cannabis compounds work differently from previous alcohol addiction treatments? Unlike failed CB1 receptor antagonists/inverse agonists, these phytocannabinoids work through varied mechanisms: CBN as a partial agonist, THCV as a neutral antagonist, and CBD as a negative allosteric modulator. This diversity in CB1 receptor interaction may provide [therapeutic benefits](https://cedclinic.com/therapeutic-benefits-of-thc/) without the severe psychiatric side effects seen with previous approaches. #### When might these cannabis-based treatments become available for patients with alcohol use disorder? This research is still in the preclinical stage using animal models, so human clinical trials would be needed before any potential therapeutic applications. The transition from promising preclinical results to approved treatments typically requires several years of clinical testing to establish safety and efficacy in humans. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Study: CBN and THCV Effective in Reducing Alcohol Intake, Outperforming CBD](https://cedclinic.com/cannabinoids-alcohol-use-disorder-cbn-thcv-study/) This study highlights the effectiveness of CBN and THCV in reducing alcohol intake, showing promising results compared to CBD. [Read the Study](https://cedclinic.com/cannabinoids-alcohol-use-disorder-cbn-thcv-study/) [Cannabis Compounds Reduce Alcohol Consumption in Rats, Study Shows – Leafie](https://cedclinic.com/cannabis-compounds-reduce-alcohol-consumption-in-rats-study-shows-leafie/) A preclinical study demonstrating how cannabis compounds can reduce alcohol consumption in animal models. [Explore Findings](https://cedclinic.com/cannabis-compounds-reduce-alcohol-consumption-in-rats-study-shows-leafie/) [CBD Beverages Linked to Reduced Alcohol Consumption: Study – DATAC](https://cedclinic.com/cbd-beverages-alcohol-reduction-study/) Research linking CBD beverage consumption to decreased alcohol intake, offering insights into potential therapeutic uses. [Learn More](https://cedclinic.com/cbd-beverages-alcohol-reduction-study/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).